The Massachusettes-based biopharma company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.
Xenetic Biosciences to validate pre-clinical data in CAR-T tech with process development exercise
Quick facts: Xenetic Biosciences
Price: 1.12 USD
Market Cap: $6.45 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE